Revolutionizing Heart Failure Treatment: The Rise of Stem Cells, GeneTherapy, and RNA-based Solutions

Abstract: This review provides a concise overview of congestive heart failure (CHF), focusing on its causes, pathophysiology, clinical manifestations, diagnosis, treatment options, and future advancements. The primary goal is to highlight key aspects of CHF management, with particular emphasis on emerging therapies aimed at improving patient outcomes. Recent studies from PubMed, Google Scholar, and Scopus were evaluated, emphasizing the relationship between etiology, pathophysiology, clinical features, diagnostic tools, and treatment strategies for CHF. Key areas include pharmacological therapies, device-based interventions, surgical approaches, lifestyle modifications, and emerging treatments, such as stem cell therapy, gene therapy, and RNA-based therapies. CHF commonly results from conditions, such as ischemic heart disease, hypertension, and cardiomyopathies, which impair cardiac function. Clinical symptoms include fatigue, shortness of breath, and fluid retention. Diagnosis relies on imaging techniques (echocardiography, MRI), biomarkers (BNP, NT-proBNP), and clinical evaluation. Standard treatment involves medications (ACE inhibitors, beta-blockers, SGLT2 inhibitors), devices (ICDs, pacemakers), and surgical interventions (CABG, valve repair). Emerging therapies, including stem cell therapy, gene therapy, and RNA-based approaches, show potential for restoring cardiac function. Prognosis depends on disease severity, comorbidities, and response to treatment. CHF is a complex condition that requires early diagnosis and targeted management. While current therapies effectively control symptoms, emerging innovations offer promise for improving long-term outcomes. Future research should focus on personalized care strategies and accessible treatments to reduce the global burden of CHF.